Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. November 2021 08:00 ET | Quelle: Oculis S.A.

Oculis Announces Patient Dosing in its First Phase 3 (DIAMOND Study - DIAbetic Macular edema patients ON a Drop) with OCS-01, a Novel, Investigational Topical Eye Drop Treatment for Diabetic Macular Edema (DME)

OCS-01 has demonstrated efficacy and safety in a Phase 2b clinical trial in DME offering the potential to become the first topical eye drop and non-invasive treatment for DME Following a positive...
07. Oktober 2021 08:00 ET | Quelle: Oculis S.A.

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence

- Dr. J. Chang, former Novartis Global Medical Affairs Head, Ophthalmology, to lead the advancement and expansion of Oculis’ pipeline development and global portfolio management - Dr. J....
11. Mai 2021 08:00 ET | Quelle: Oculis S.A.

Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021

Positive Phase 2a data, presented for the first time, highlights the potential of OCS-02 to become a new treatment in moderate to severe DED and potentially the first personalized therapy in this...
04. Mai 2021 08:00 ET | Quelle: Oculis S.A.

Oculis Announces an Oversubscribed US$57 million Series C Financing

New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01 and OCS-02 and deliver the...
24. November 2020 08:00 ET | Quelle: Oculis S.A.

Oculis to Present Progress in its Portfolio of Novel Topical Treatments for Retinal and Front-of-the-Eye Diseases at Upcoming Investor Conferences

LAUSANNE, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of...
22. Oktober 2020 08:00 ET | Quelle: Oculis S.A.

Oculis appoints David Jacobs, M.D. as Chief Development Officer adding complementary drug development and regulatory expertise

LAUSANNE, Switzerland, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of...
05. Oktober 2020 08:00 ET | Quelle: Oculis S.A.

Oculis announces presentation of positive results from Phase 2 trial of OCS-01 in patients with Diabetic Macular Edema (DME) at EURETINA 2020 Virtual

The study met its pre-specified efficacy endpoints and showed that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with...
22. September 2020 08:00 ET | Quelle: Oculis S.A.

Oculis to present significant corporate and clinical development progress at upcoming biotech and ophthalmology conferences

LAUSANNE, Switzerland, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives...
27. Juli 2020 08:00 ET | Quelle: Oculis S.A.

Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications

Dr. David P. Bingaman Appointed as Vice President, Global Clinical Development LAUSANNE, Switzerland, July 27, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on...